Professional Experience Scott K. Reed is Chair of the firm's Litigation Practice Group. His practice focuses on the trial and appeal of complex patent litigations for technology leaders including Bausch & Lomb, Bristol Myers Squibb, Canon, DuPont, Emory University, Genzyme, GlaxoSmithKline, IBM, Merck, Mitsui, Novartis, Pfizer, Quebec Metal Powders, Regeneron, sanofi-aventis, UCB Pharma and Union Carbide. Mr. Reed has extensive trial experience and has served as lead trial counsel in cases involving pharmaceuticals, biotechnology, chemicals and electronic and computer technologies. Mr. Reed also presently serves on the firm's Management Committee. Awards and Recognition Scott K. Reed was listed in Legal Media Group Guide to the World's Leading Patent Law Practitioners 2007-2010. He was listed in Legal 500 2007-2010 for Patent litigation: life sciences/chemical. He was also listed in IAM 250: The World's Leading Patent Litigators 2011. For information on the selection process, see: Legal 500 Legal Media Group Expert Guides IAM 250 Professional Activities American Bar Association; American Intellectual Property Law Association; Federal Bar Counsel; Federal Circuit Bar Association; New York Intellectual Property Law Association Representative Matters · Bausch & Lomb in Bausch & Lomb v. Alcon and Bausch & Lomb v. Allergan (contact lens care products containing proteolytic enzymes and antimicrobial agents), Visx v. Bausch & Lomb (laser eye surgery), Allergan v. Bausch & Lomb (intraocular lenses), Allergan v. Bausch & Lomb (anti-glaucoma pharmaceuticals), Bausch & Lomb v. GNC, Bausch & Lomb v. Leiner, Bausch & Lomb v. Alcon, and Bausch & Lomb v. Rexall (nutritional supplement to treat Macular Degeneration) · Bristol-Myers Squibb in Regents of the University of Michigan and Repligen Corporation v. Bristol-Myers Squibb (fusion protein regulation of the immune system), Housey Pharmaceuticals v. Bristol-Myers Squibb (cell based biotechnology assays), Zymogenetics v. Bristol-Myers Squibb (fusion proteins) and Regents of the University of Michigan and Repligen Corporation v. Bristol-Myers (rheumatoid arthritis pharmaceuticals) · Canon in Honeywell v. Canon (autofocus camera technology) and Gross v. Canon (microprocessor technology and optical devices) · DuPont in Schneider v. DuPont and DuPont v. Cordis (polymeric balloon angioplasty materials) · Emory University in Emory University v. Glaxo Wellcome (anti-hepatitis pharmaceuticals) and Emory University v. Glaxo Wellcome and BioChem Pharma (anti-AIDS pharmaceuticals) · Genzyme in Bonecare and Genzyme v. Pentech, Eagle, Sandoz, Anchen, and Roxane (kidney disease pharmaceuticals); Bonecare and Genzyme v. Impax, Lupin, Endo, Teva, Watson, and Sandoz (kidney disease pharmaceuticals); Daiichi-Sankyo and Genzyme v. Impax and Lupin (anti-cholesterol pharmaceuticals). · GlaxoSmithKline in GlaxoSmithKline v. Barr (prostate pharmaceuticals); Pozen v. Par (migrane pharmaceuticals) · IBM in Berkeley v. IBM (personal computers); Valutron v. IBM (point of sale devices) · Merck in Merck v. Alcon (anti-glaucoma pharmaceuticals) · Mitsui in 3M v. Mitsui (adhesive technology) · Novartis in Novartis v. Abbott (organ transplant cyclosporin pharmaceuticals) · Pfizer in Pfizer v. Barr (estrogen contraceptive pharmaceuticals) and Pfizer v. Barr (hormone replacement therapy pharmaceuticals) · Regeneron in Regeneron v. Genentech (macular degeneration pharmaceuticals) · sanofi-aventis in Genentech v. Sanofi and Regeneron (anti-cancer pharmaceuticals) · Quebec Metal Powders in Hoeganaes v. Quebec Metal Powders (powder metallurgy) · UCB in UCB v. Mylan, UCB v. Dr. Reddy's, UCB v. Ivax, UCB v. Sandoz and UCB v. Cobalt (epilepsy pharmaceuticals); UCB v. KV (attention deficit disorder pharmaceuticals) · Union Carbide in BP v. Union Carbide (polythylene processing technology) Decisions Representative Cases UCB Societe Anonyme & UCB Pharma Inc. v. Mylan Laboratories, Inc. et al.
N.D. GA 2006 The Regents of the University of Michigan and Repligen Corp. v. Bristol-Myers Squibb
Fed. Cir. 2004 Housey Pharmaceuticals v. Bristol-Myers Squibb Co.
Fed. Cir. 2004 The Regents of the University of Michigan and Repligen Corp. v. Bristol-Myers Squibb Co.
E.D. Mich. 2003 Allergan v. Bausch & Lomb and Alcon
C.D. Cal., 2002 Housey Pharmaceuticals v. Bristol-Myers Squibb Co.
D.Del 2002 Bausch & Lomb, Inc. v. Alcon Laboratories, Inc.
W.D.N.Y. 1999 Publications/Events Events C5's 21st Forum on Biotech Patenting
C5
October 5-6, 2011 5th Annual Pharmaceutical & Biotech Patent Litigation Strategies Conference
IQPC
Partners Scott K. Reed and Ha Kung Wong to speak at Biotech Conference in London
May 24-26th, 2010 Key Factors in Long-Term Lawyer-Client Relationships
AIPLA 2008 Mid-Winter Institute
January 24, 2008 Latest Legislative and Judicial Updates Impacting US Pharma Industry
5th Annual Pharmaceutical Patent Life Cycles Conference
January 20, 2006 Claim Construction
NYIPLA/Federal Circuit Bar Association Conference
October 14, 2005 Practical Tips for Jury Trials in Patent Cases
2004 AIPLA Mid-Winter Institute
January 2004 What Every IP Lawyer Should Know About How to Conduct a Trial in the Digital Decade
American Intellectual Property Law Association's 2004 Mid-Winter Institute
January 28-31, 2004 Exclusivity: Who Can Stay and Who Can Play
Legal Strategies for Maximizing Pharmaceutical Patent Life Cycles Conference
April 1, 2003 |